By the Numbers: Patients lose when the government sets prices
Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At […]
Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At […]
Inflation is causing pain for people across the country. As policymakers search for ways to help provide relief, some are erroneously tying inflation to prescription […]
In comments submitted to the Federal Trade Commission (FTC), PhRMA urged the agency to examine how pharmacy benefit managers (PBMs) leverage their extraordinary power to […]
More than 1,150 medicines were excluded from at least one of the three largest PBMs’ standard commercial formularies in 2022, according to a new report […]
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned […]
The Centers for Medicare & Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. […]
New data show how robust competition continues to keep national spending on life-saving medicines in check, even as new innovative treatments reach patients. According to […]
A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent […]
According to a new Ipsos/PhRMA poll, most Americans — 82% — agree that lowering out-of-pocket costs for health care should be a top priority for […]
While insurers negotiate steep discounts on medicines, they don’t always share these savings directly with patients. In recent years, insurers have shifted costs for brand […]
Last week, the Senate Finance Committee held a hearing focused on drug prices where the discussion was filled with misleading claims. We agree too many […]
A new study by GlobalData looked at brand oral antidiabetic drugs (OADs) and found that sharing negotiated rebates with patients in commercial health plans at […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet […]
Concerns about inflation continue to be top of mind for many Americans, as prices for basic services and necessities climb at a rapid pace. But there […]
The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. […]
The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances […]
A new large-scale survey of 20,000 Americans covering all states and Congressional districts shows a majority find health care coverage costs unreasonable and a top […]
The Congressional Budget Office (CBO) recently released a new report looking at trends in spending, prices and use of prescription drugs. While some politicians are […]
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis […]
Last week, the Centers for Medicare & Medicaid Services (CMS) released National Health Expenditures (NHE) data that show net prices for retail prescription medicines declined, […]
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
Last week, a congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. […]
As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended […]
For months Congress has been debating massive changes to the nation’s social safety net, one of which is the highly popular Medicare prescription drug benefit. […]
A recent Centers for Medicare & Medicaid Services (CMS) study found that medication use is improving among seniors and vulnerable beneficiary populations. Better adherence to medicines used […]
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could […]
As the debate in Washington around drug pricing proposals continues to intensify, a new Ipsos/PhRMA poll shows Medicare “negotiation” is not nearly as popular as […]
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending […]
For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access […]
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C […]
A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. […]
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, […]
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the […]
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and […]
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health […]
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that […]
A recent analysis by Health Advances looks at two particularly burdensome hematological (or blood) diseases — beta thalassemia and hemophilia A — and finds that potential […]
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment […]
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than […]
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their […]
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas […]
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has […]
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The […]
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across […]
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) […]
Copyright © 2024 | WordPress Theme by MH Themes